Cancer Stemness in Apc- vs. Apc/KRAS-Driven Intestinal Tumorigenesis by Ghazvini, M. (Mehrnaz) et al.
Cancer Stemness in Apc- vs. Apc/KRAS-Driven Intestinal
Tumorigenesis
Mehrnaz Ghazvini1, Petra Sonneveld1, Andreas Kremer2, Patrick Franken1, Andrea Sacchetti1,
Yaser Atlasi1, Sabrina Roth1, Rosalie Joosten1, Ron Smits3, Riccardo Fodde1*
1Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands, 2Department of Bioinformatics, Erasmus MC, Rotterdam, The
Netherlands, 3Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands
Abstract
Constitutive activation of the Wnt pathway leads to adenoma formation, an obligatory step towards intestinal cancer. In
view of the established role of Wnt in regulating stemness, we attempted the isolation of cancer stem cells (CSCs) from Apc-
and Apc/KRAS-mutant intestinal tumours. Whereas CSCs are present in Apc/KRAS tumours, they appear to be very rare
(,1026) in the Apc–mutant adenomas. In contrast, the Lin2CD24hiCD29+ subpopulation of adenocarcinoma cells appear to
be enriched in CSCs with increased levels of active b-catenin. Expression profiling analysis of the CSC-enriched
subpopulation confirmed their enhanced Wnt activity and revealed additional differential expression of other signalling
pathways, growth factor binding proteins, and extracellular matrix components. As expected, genes characteristic of the
Paneth cell lineage (e.g. defensins) are co-expressed together with stem cell genes (e.g. Lgr5) within the CSC-enriched
subpopulation. This is of interest as it may indicate a cancer stem cell niche role for tumor-derived Paneth-like cells, similar
to their role in supporting Lgr5+ stem cells in the normal intestinal crypt. Overall, our results indicate that oncogenic KRAS
activation in Apc-driven tumours results in the expansion of the CSCs compartment by increasing H-catenin intracellular
stabilization.
Citation: Ghazvini M, Sonneveld P, Kremer A, Franken P, Sacchetti A, et al. (2013) Cancer Stemness in Apc- vs. Apc/KRAS-Driven Intestinal Tumorigenesis. PLoS
ONE 8(9): e73872. doi:10.1371/journal.pone.0073872
Editor: Cara Gottardi, Northwestern University Feinberg School of Medicine, United States of America
Received March 8, 2013; Accepted July 24, 2013; Published September 17, 2013
Copyright:  2013 Ghazvini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. These studies were
supported by grants from the Dutch Cancer Society (EMCR 2001-2482), the Netherlands Organisation for Scientific Research (NWO/Vici 016.036.636), the BSIK
(Kennisinfrastructuur) program of the Dutch Government grant 03038 (www.stemcells.nl) and the Netherlands Institute for Regenerative Medicine (NIRM; www.
nirm.nl), and the EU FP6 and FP7 consortia Migrating Cancer Stem Cells program (MCSCs; www.mcscs.eu) and TuMIC (integrated concept of tumor metastasis
(http://itgmv1.fzk.de/www/tumic/tumic_main.htm).
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: r.fodde@erasmusmc.nl
Introduction
Colon cancer still represents an ideal model to study the
molecular and cellular mechanisms that underlie tumour onset
and progression towards malignancy [1], the so-called adenoma-
carcinoma sequence [2]. Overall, loss-of-function mutations in the
APC (adenomatous polyposis coli) tumour suppressor gene or
oncogenic mutations in b-catenin (CTNNB1) lead to the constitu-
tive activation of Wnt/b-catenin signalling and represents the most
common rate limiting (adenoma-forming) events among colon
cancer patients. Adenoma growth and progression is often
accompanied by alterations in KRAS or BRAF, followed by loss
of the TP53 and SMAD4 tumour suppressors thought to underlie
the malignant transformation into locally invasive adenocarcino-
ma [1]. However, this well established genetic evolution model
does not take into account other essential characteristics of human
colon cancers, namely their cellular heterogeneity (different cell
lineages are often present within the primary mass) and the
putative role played by a subpopulation of tumour cells, the cancer
stem cells (CSCs), in driving tumour growth and determining local
invasion into surrounding tissues and distant metastasis [3]. In fact,
although the above genetic model would predict that every tumour
cell within a colon cancer allegedly initiated by an APC or b-
catenin mutation should invariably be earmarked by the hallmark
of constitutive Wnt activation, namely nuclear b-catenin accumu-
lation, this is only observed in a minority of cells usually located at
the invasive front of the primary lesion [4] from where they detach
and invade the surrounding stroma [5,6]. This ‘‘b-catenin
paradox’’ nicely illustrates how intra-tumour heterogeneity and
possibly tumour stemness ensue at the very initial stages of the
adenoma-carcinoma sequence and lead to different Wnt signalling
levels among different tumour cells lineages sharing the same
(APC) mutations [7]. It also indicates that loss of APC function (or
oncogenic b-catenin activation) is presumably necessary for the
onset of the initial dysplastic lesion but insufficient to fully activate
Wnt signal transduction and promote malignant transformation in
the absence of additional environmental and (epi)genetic factors.
Previously, by employing in vivo mutagenesis [8,9] and gene
targeting in the mouse [10,11], it was shown that loss of Apc
function results in adenoma formation in the upper GI tract.
However, these mouse adenomas fail to progress to malignancy
and do not spontaneously accumulate additional genetic hits at the
endogenous Kras and Tp53 genes [12]. Notably, whereas
oncogenic KRAS activation on its own is unable to initiate
intestinal tumorigenesis if not with very late onset and only upon
somatic hits at the Tp53 gene [13], compound Apc1638N/+/
KRASV12G mice are characterized by a 10-fold increase in tumour
multiplicity and by accelerated tumour progression when
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compared with Apc1638N/+ littermates, with the vast majority of the
tumour lesion being represented by adenocarcinomas [14].
Further analyses revealed that Apc and KRAS mutations are
synergistic in promoting b-catenin nuclear translocation, thus
enhancing canonical Wnt signal transduction [14]. The latter is
likely to result from the ability of activated KRAS, through
downstream and yet unknown kinases, to induce b-catenin
tyrosine phosphorylation thus leading to a substantial increase of
its cytoplasmatic pool and its subsequent translocation to the
nucleus where it acts as a transcriptional activator of several Wnt
downstream target genes. Accordingly, intestinal tumours from
Apc1638N/+/KRASV12G mice show a significant increase in cells with
nuclear accumulation of b-catenin when compared with Apc1638N/
+ animals [14].
In recent years, CSCs have been successfully purified from
human colon cancers by employing different cell surface markers
such as CD133 [15,16], EpCAM, CD44 and CD166 [17], and
EphB2 [18]. However, although the above cell surface antigens
have been instrumental for the identification of tumour cell
subpopulations with enriched tumour-initiating properties when
transplanted into immune-incompetent recipient mice, our
understanding of the mechanisms underlying intestinal cancer
stemness and of the role played by CSCs in progression towards
malignancy is still largely incomplete. Previously, Vermeulen et al.
showed that high Wnt activity earmarks CSCs within suspension
spheres derived from colon tumors [19]. From this perspective, a
number of additional issues need to be addressed: is nuclear b-
catenin accumulation a functional marker for intestinal CSCs
in vivo? Are tumor cells with stem-like properties already present in
early, benign lesions such as adenomas? Here, we took advantage
of the Apc1638N/+ and Apc1638N/+/KRASV12G mouse models for
intestinal tumorigenesis to prospectively identify subpopulations of
tumour stem-like cells and characterize them with regard to their
multipotency, self-renewal, genome-wide expression profile, and
Wnt/b-catenin signalling activity.
Results
Tumour-initiating Cells are Present in Apc1638N/+/KRASV12G
but are Very Rare in Apc1638N/+ Intestinal Tumours
The Apc1638N/+ mouse model develops an average of 4–5 benign
upper GI tumours (adenomas) in the C57Bl/6J genetic back-
ground [10,11]. These lesions only rarely (and with late onset)
develop into adenocarcinomas as also shown by the lack of
spontaneous somatic mutations occurring at the Kras and Tp53
genes [12]. To assess the presence of tumour-initiating cells in
Apc1638N/+ adenomas, i.e. cells capable of recapitulating the
primary lesion when transplanted into a recipient animal,
intestinal tumours were collected from Apc1638N/+ animals and
dissociated both mechanically and enzymatically into single cell
suspensions and depleted from endothelial and hematopoietic cells
(Lin+) by fluorescence-activated cell sorting (FACS). Next, different
multiplicities of the resulting Lin2 population of bulk tumour cells
were transplanted subcutaneously into NOD-SCID animals. As
shown in Table 1, no tumour growth was observed even upon
injection of as many as 0.5–1.0*106 Lin- cells and 6 months after
transplantation.
Next, we repeated the transplantation assay with bulk Lin2
tumour cells from Apc1638N/+/KRASV12G intestinal tumours. As
previously reported, the majority of the intestinal tumours found in
these compound animals in the same inbred C57B6/J genetic
background are locally invasive adenocarcinomas [14]. In sharp
contrast with the Lin- cells from Apc1638N/+ adenomas, tumour
growth was observed in 23 out of 33 injections with 105 Apc1638N/
+/KRASV12G Lin- cells and, though at lower incidence (3 out of 48
transplantations), even with as low as 1500 cells (Table 1). By
limiting dilution analysis (L-CalcTM) the frequency of tumour-
initiating cells in the Lin2 population from Apc1638N/+/KRASV12G
intestinal tumours was estimated as 1 in 72838 (95% CI of 109467
to 48465). As for the Apc1638N/+ adenomas, tumour-initiating cells
are likely to be present, if at all, at considerably lower frequencies
(,1026). Hence, the presence of tumour-initiating cells, as defined
by transplantation assays, appears to be limited to the tumours
from Apc1638N/+/KRASV12G mice when compared with those from
the Apc1638N/+ mouse model.
The Lin-CD24hiCD29+ Subpopulation from Apc1638N/+/
KRASV12G Intestinal Tumours Encompass Tumour-
initiating and Self-renewing CSCs
In order to prospectively enrich and eventually isolate tumour-
initiating cells from the bulk Lin- population of Apc1638N/+/
KRASV12G tumours, we first tested a panel of previously established
(cancer) stem cell markers including CD24, CD29 (b1 integrin),
CD44, CD97, and L1CAM by FACSorting and subsequent
transplantation in NOD-SCID mice. In contrast to CD44,
L1CAM, and CD97 (Table S1), transplantation of
Lin-CD24+CD29+ cells revealed a slight yet significant enrichment
in tumour-initiating cells (estimated frequency of 1 in 56463, with
CI of 399211 to 7986) (Table 2). Given that the Lin-CD24+CD29+
population represents a relatively large proportion of the bulk cells
(,80%; data not shown), we then further defined three additional
FACS gates based on the relative expression of the CD24 cell
surface antigen (CD24hi, CD24med, and CD24low) (Figure 1a). Out
of 30 primary Apc1638N/+/KRASV12G tumours analysed by FACS,
the average size (expressed in percentage of the bulk Lin2 fraction)
of each CD24/CD29 sorted subpopulation was determined:
CD242CD292, 3.4% (SD 2.6); CD242CD29+, 7.8% (SD 4.7);
CD24+CD292, 4.4% (SD 3.4); CD24loCD29+ (P1), 7.9% (SD 2.5);
CD24medCD29+ (P2), 52.9% (SD 7.4); CD24hiCD29+ (P3), 10.0%
(SD 4.7). Please note that these percentages do not add to 100%
simply because of the deliberate exclusion of cells located in the
separations between sorting gates (see Figure 1a).
The frequency of tumour-initiating cells within the P1, P2 and
P3 subpopulations was determined by transplanting 1500 cells of
Table 1. Subcutaneous transplantation of bulk intestinal
tumor cells in immune-incompetent mice indicates the
presence of CSCs in Apc1638N/+/KRASV12G but not in Apc1638N/+
tumours.
Sorted tumor
population
No. of
transplanted cells
Tumors in
NOD/SCID
Apc1638N/+ Lin2 (bulk) 1.06106 0/1
Apc1638N/+ Lin2 (bulk) 5.06105 0/7
Apc1638N/+ Lin2 (bulk) 3.06 105 0/6
Apc1638N/+ Lin2 (bulk) 2.56105 0/6
Apc1638N/+ Lin2 (bulk) 1.06105 0/12
Apc1638N/+/KRASV12G
Lin2 (bulk)
1.06105 23/33
Apc1638N/+/KRASV12G
Lin2 (bulk)
5.06103 2/16
Apc1638N/+/KRASV12G
Lin2 (bulk)
1.56103 3/48
doi:10.1371/journal.pone.0073872.t001
Apc and KRAS Synergize in Cancer Stemness
PLOS ONE | www.plosone.org 2 September 2013 | Volume 8 | Issue 9 | e73872
each into NOD-SCID mice. Notably, whereas at this multiplicity
CD24medCD29+ and CD24loCD29+ cells consistently failed to
form tumours (only 1 growth out of 56 transplantations), the
Lin-CD24hiCD29+ subpopulation was found to encompass a
substantial enrichment in tumorigenic cells (13/28; Table 2).
Hence, although in this case we could not perform limiting
dilution analysis by L-CalcTM (since a fixed multiplicity of cells was
employed) the Lin-CD24hiCD29+ tumour subpopulation appears
to be characterized by a significant relative enrichment of approx.
20–25 fold when compared with total Lin- bulk cells (1 CSC out of
,3000 tumour cells vs. 1 in 72838).
The definition of cancer stem cells cannot be exclusively based
on their ability to form tumours when transplanted at low
multiplicity in immune-incompetent mice. Equally important
characteristics of CSCs are their unique ability to self-renew and
differentiate to fuel and recapitulate the heterogeneous composi-
tion of the primary tumour they are derived from. In order to
determine whether the tumour-initiating cells encompassed by the
Figure 1. FACS analysis of cell suspensions from Apc1638N/+/KRASV12G tumours. a. Large panel: dot plot representative of the staining
pattern obtained by staining with anti-CD24 APC-conjugated and anti-CD29 PE-conjugated antibodies. Lineage positive cells (Lin+) were excluded
(gated out) by staining with biotinylated antibodies against lineage markers and Streptavidin-PerCPCy5.5. P1 (Lin2CD24lowCD29+), P2
(Lin2CD24medCD29+), and P3 (Lin2CD24hiCD29+) populations are indicated in the plot. Small panels: dot plots representative of cells stained with
isotypic control antibodies (left), compensation control stained only with anti CD24-APC antibodies (middle), compensation control stained only with
anti CD29-PE antibodies (right). b. FACS analysis of the CD24/CD29 pattern of tumours obtained by serial transplantation of P3 cells suspensions from
Apc1638N/+/KRASV12G intestinal tumours. Left: primary transplantation. Right: secondary transplantation. c. Immunohistochemistry analysis of tumors
obtained by 3 rounds of serial transplantation of P3 cells suspensions from Apc1638N/+/KRASV12G intestinal tumours.
doi:10.1371/journal.pone.0073872.g001
Apc and KRAS Synergize in Cancer Stemness
PLOS ONE | www.plosone.org 3 September 2013 | Volume 8 | Issue 9 | e73872
Lin-CD24hiCD29+ population are also capable of self-renewal and
differentiation, we performed serial transplantations experiments.
First, 1500 Lin-CD24hiCD29+ cells were isolated from Apc1638N/+/
KRASV12G primary intestinal tumours and transplanted in NOD-
SCID recipient mice. As anticipated from our previous results, this
initial assay gave rise to subcutaneous tumours within 8 to 10
weeks. The resulting tumours were then excised from the recipient
NOD-SCID animals and employed for both FACS and histolog-
ical analysis. As for FACS, tumours were dissociated into single
cell suspensions and analysed, sorted and transplanted according
to their CD24 and CD29 expression levels. Secondary tumours
originated from Lin-CD24hiCD29+ cells fully recapitulated the
CD24/CD29 FACS expression profile of the primary lesions
(Figure 1b and Figure S2). Likewise, upon transplantation of 1500
cells from each of the Lin2CD24CD29 populations obtained from
the secondary tumours, only the Lin2CD24hiCD29+ cells were
capable of forming tertiary tumours. Accordingly, the FACS
profile of the tertiary tumours recapitulates that of the primary
lesions (Figure 1b). Notably, immunohistochemistry (IHC) and
enzymatic staining revealed a progressive increase in the relative
presence of intestinal differentiation lineages, namely Goblet
(Periodic Acid Schiff; PAS), Paneth (lysozyme), and entero-
endocrine (synaptophysin) cells in the transplanted intestinal
tumours when compared with the primary Apc1638N/+/KRASV12G
lesions (Figure 1c). However, FACS analysis of the serially
transplanted tumours showed that the relative size of the
individual CD24/CD29 subpopulations did not significantly
changed (Figure S3).
Thus, the Lin-CD24hiCD29+ subpopulation of tumour cells
from Apc1638N/+/KRASV12G adenocarcinomas encompass bona fide
CSCs with tumour-initiating, self-renewing and differentiation
capacities.
Lin-CD24hiCD29+ Cells from Apc1638N/+/KRASV12G Intestinal
Tumours Show Increased Intracellular b-catenin
Accumulation
We previously proposed that the minority of colon cancer cells
featuring nuclear b-catenin accumulation and non-randomly
distributed along the invasive front, represent CSCs [7]. Notably,
both Apc1638N/+ adenomas and Apc1638N/+/KRASV12G carcinomas
share the same ‘‘b-catenin paradox’’ observed in human colon
cancers in that, upon IHC analysis, only a minority of tumour cells
show nuclear b-catenin accumulation notwithstanding that the
majority, if not all, share the two-hits at the Apc locus [12,14]
(Figure 2a). To assess whether the CSCs enriched in the
Lin2CD24hiCD29+ tumour subpopulation are characterized by
an increased level of intracellular b-catenin, we analysed protein
expression in the different FACSorted tumour cell subpopulations
by two independent assays, namely immuno-staining and western
blot analysis. Immuno-staining showed that the majority of
Lin-CD24hiCD29+ intestinal tumour cells are characterized by
intracellular accumulation of b-catenin when compared with other
sorted populations and the bulk (Lin2) tumour cells (Figure 2b).
This result was also confirmed in a more quantitative fashion by
western analysis performed with antibodies specific for the
signalling-competent fraction (i.e. dephosphorylated at residues
Ser37 and Thr41) of the b-catenin protein (Figure 2c and Figure
S4).
Overall, these data confirm that the Lin-CD24hiCD29+
subpopulation from Apc1638N/+/KRASV12G tumours, here shown
to be enriched in CSCs, encompasses a significantly higher level of
intracellular and signalling-competent b-catenin when compared
to bulk Lin2 and other tumour cell subpopulations. The increased
Wnt signalling activity in CSCs was later confirmed by expression
profiling and Taqman qPCR analysis of Wnt downstream target
genes (e.g. Lgr5, Axin2, T, and Lef1; see here below).
The Expression Signature of CSCs from Apc1638N/+/
KRASV12G Intestinal Tumours is Distinct from that of
Differentiated and Bulk Tumour Cells and Encompasses
Both Stem and Paneth Cell Markers
To identify molecular differences between stem-like and more
differentiated (bulk) tumour cells from Apc1638N/+ and Apc1638N/+/
KRASV12G intestinal tumours, we isolated total RNA from 104
Lin-CD24hiCD29+ (P3), Lin-CD24medCD29+/Lin2CD24loCD29+
(P1+P2, merged gate) and Lin- (bulk) tumour cells from 5
individual mice of each genotype (Apc1638N/+ and Apc1638N/+/
KRASV12G). Total RNA samples were then employed to hybridize
oligonucleotide microarrays (Affymetrix Mouse Genome 430A 2.0
Array) according to conventional protocols.
First, the different tumour cell populations isolated from mice
with different genotypes (Apc1638N/+ and Apc1638N/+/KRASV12G)
were compared by ANOVA (3 ways) with a FDR (false discovery
rate) set at 0.05 to select for genes with $2-fold differential
expression. Notably, the P3 (CSCs from both genotypes) vs. Lin2
(bulk; both genotypes) and P3 vs. P1+P2 comparisons resulted in
significant differences and in the definition of two lists of
differentially expressed probe sets (n = 1062 [851 non-redundant,
annotated genes] and 746 [602 non-redundant, annotated genes],
respectively; Tables S3 and S4). In this fashion, we identified a list
of 587 differentially expressed probe sets from the intersection of
the Lin- vs. P3 and P1+P2 vs. P3. The identified probe sets
correspond to 482 genes (non-redundant) (Table S5).
The expression profiles obtained from the CSC-enriched
subpopulations (Lin2CD24hiCD29+) of both genotypes
(Apc1638N/+ and Apc1638N/+/KRASV12G) differ from those of more
differentiated (Lin2CD24medCD29+/CD24loCD29+) and of the
Lin2 bulk subpopulations as clearly visible in the hierarchical
clustering (HCA) and principal component (PCA) analysis
(Figure 3).
Notably, the Apc- and Apc/KRAS-mutant genotypes are not
resolved by HCA and PCA, possibly due to the relatively limited
number of Apc1638N/+ and Apc1638N/+/KRASV12G tumour samples
(n = 5 for each group) employed for the comparative expression
Table 2. Subcutaneous transplantation of sorted cells from
Apc1638N/+/KRASV12G tumours in immune-incompetent mice
indicates the presence of tumor-initiating cells in the
CD24hiCD29+ subpopulation.
Sorted tumor
population
No. of
transplanted cells
Tumors in
NODSCID
Lin2CD24+CD29+ 5.06103 8/24
Lin2 depleted
of CD24+CD29+
5.06103 1/10
Lin2CD24+CD29+ 1.56103 3/30
Lin2 depleted
of CD24+CD29+
1.56103 0/6
Lin2CD24lowCD29+ 1.56103 1/28
Lin2CD24medCD29+ 1.56103 0/28
Lin2CD24hiCD29+ 1.56103 13/28
doi:10.1371/journal.pone.0073872.t002
Apc and KRAS Synergize in Cancer Stemness
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Figure 2. b-catenin expression analysis in Apc1638N/+ and Apc1638N/+/KRASV12G intestinal tumours. Immuno-histochemistry (a.,b.) and
western blot (c.) analysis of b-catenin in primary Apc1638N/+ intestinal adenomas (a.) and in FACSorted tumour populations from Apc1638N/+/KRASV12G
Apc and KRAS Synergize in Cancer Stemness
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profiling analysis, insufficient to highlight the allegedly more subtle
differences between benign and malignant CSCs.
Next, from the above lists of differentially expressed probes
between the P3 and other tumour cell populations we validated
the expression of a total of 35 genes by quantitative real-time PCR
(Table S2). The selection of validated genes includes, apart from
the top up- and down-regulated genes, also additional members of
the canonical Wnt signal transduction pathway, and genes known
to play relevant roles in cancer. Overall, the vast majority of the
selected genes (33/35) were validated for their differential
expression by qPCR (Figure S1).
Gene ontology analysis [20] of the intersection signature
revealed a rather broad spectrum of cellular functions, structures
and processes among the up-regulated genes including extracel-
lular matrix, cell adhesion, organ development and morphogenesis
(Table S6). In particular, analysis of the genes differentially
expressed in the CD24hiCD29+ cells from Apc1638N/+ and
Apc1638N/+/KRASV12G tumours in comparison with bulk and more
differentiated tumour cells, revealed several biological processes
likely to play functional roles in cancer stemness. First, as also
shown by the intracellular accumulation of active b-catenin,
several targets and members of the Wnt signalling cascade are
differentially expressed in the P3 signature including Lgr5, Mmp2
and Mmp7, Dkk2, Pla2g2a, Prox1, Sox17, T (brachyury), Wif1, and
Fzd5. The presence of Lgr5 among the upregulated genes is of
interest as it indicates that this well-known marker of normal
cycling stem cells in the mouse intestine [21] might also represent a
useful CSC marker in mouse intestinal tumours as recently
demonstrated by lineage tracing [22]. Also, the transcription factor
Prox1, a direct and dose-dependent target of the Wnt/b-catenin
signalling pathway, was upregulated in the P3 population. Prox1
was previously shown to promote dysplasia in colonic adenomas
and colorectal cancer progression [23]. However, we could not
find any significant differences between Prox1 expression levels
between Apc1638N/+ and Apc1638N/+/KRASV12G tumour cells both
in the original microarray data and upon qPCR validation (Figure
S1). This observation reflects a more general lack of significant
differences between the P3 populations of Apc1638N/+ and
Apc1638N/+/KRASV12G tumours, as also shown by hierarchical
clustering and PCA analysis (Figure 3a and b, respectively). In our
previous study [14], expression profiling of bulk tumours from
Apc1638N/+ and Apc1638N/+/KRASV12G mice also did not resolve the
two genotypes. In fact, only the relative number of tumour cells
with nuclear b-catenin could significantly distinguish between
Apc1638N/+ from Apc1638N/+/KRASV12G intestinal tumours [14].
Apart from Wnt, additional signalling pathways are represented
by the differentially regulated genes as shown by the differential
expression of Bmp7 and Bmper (Bmp signaling), Fgfbp1, Fgfrl1, and
Etv5 (fibroblast growth factor receptors, binding proteins and
transcription factors), and Igf1, Igfbp1, Igfbp5, and Igfbp7 (insulin-
like growth factors and binding proteins).
Overall, these results show that CSCs from Apc- and Apc/KRAS-
mutant tumours have distinct expression profiles from other
tumour cell populations and are characterized by increased Wnt
signalling activity, in agreement with their enhanced levels of
intracellular b-catenin, together with other signalling pathays
(Bmp, Igf), and by the expression of Paneth cell-specific genes.
Discussion
Mutations in the APC tumour suppressor gene represent the
main initiating and rate-limiting event in the adenoma-carcinoma
sequence leading to colon cancer in man [1]. Loss of APC function
leads to the constitutive activation of the canonical Wnt/b-catenin
signalling pathway known to play crucial roles in the regulation of
self-renewal and differentiation in a broad spectrum of tissue-
specific stem cell niches including the intestinal crypt and,
accordingly, in the onset of many cancer types [24]. Constitutive
Wnt signalling activation in the intestinal epithelium triggers
adenoma formation and represents a necessary, though insuffi-
cient, step for malignant transformation. Somatic mutations in
KRAS, BRAF, TP53, and SMAD4 usually underlie the further
progression of the benign tumour into locally invasive adenocar-
cinoma and metastasis at distant organ sites [1]. Mutations in the
endogenous mouse Apc gene also lead to intestinal polyp
formation, though mainly located in the upper GI tract. Notably,
mouse Apc-driven intestinal adenomas do not spontaneously
accumulate Kras or Tp53 somatic mutations and, accordingly,
very rarely progress to adenocarcinomas [12].
In our laboratory, we have generated the Apc1638N/+ mouse
model encoding for a hypomorphic Apc mutation resulting in few
(5–6) upper GI adenomas, longer survival, and an increased
chance of spontaneous malignant transformation though only in
animals older than 1 year [10,11,12]. In contrast, compound
heterozygous Apc1638N/+/KRASV12G mice are characterized by
increased tumour multiplicity (,10 fold) and accelerated malig-
nant progression with the majority of lesions being locally invasive
adenocarcinomas [14]. Notably, oncogenic activation of KRAS/
Kras on its own is insufficient to initiate intestinal tumorigenesis
[25], if not with late onset and upon somatic inactivation of the
Tp53 gene [13]. Hence, the dramatic phenotypic differences
brought about by oncogenic activation of the KRAS gene in
compound Apc1638N/+/KRASV12G mice results from its synergistic
action in promoting canonical Wnt signalling, as shown by the
increase in TOP-Flash reporter activity and in the number of
tumour cells earmarked by nuclear b-catenin accumulation [14].
The observed relative increase in the number of Apc1638N/+/
KRASV12G tumour cells earmarked by nuclear b-catenin is of
importance in view of the so-called ‘‘b-catenin paradox’’ [7]:
notwithstanding the fact that loss of APC function is common to all
tumour cells and is predicted to result in the intracellular and
nuclear accumulation of b-catenin, this is only observed in a
minority of cancer cells undergoing an epithelial-to-mesenchymal
transition (EMT) and non-randomly distributed at the invasive
front of the tumour mass [4,5] (see also Fig. 2a). This observation
led to the hypothesis according to which nuclear b-catenin
earmarks stem-like intestinal tumour cells with higher Wnt
signalling activity capable of detaching from the primary mass
and efficiently disseminate and home in distal, vital organs
[6,19,26].
Here, we attempted the prospective purification of cancer stem
cells (CSCs) from Apc1638N/+/KRASV12G intestinal tumours.
Notably, the presence of tumour-initiating cells, could not be
demonstrated in Apc1638N/+ tumours. According to the operational
CSC definition, namely their capacity to form tumours upon
limiting dilution transplantation into recipient mice, bona fide CSCs
are either absent or extremely rare (.1026) in the intestinal lesions
characteristic of Apc1638N/+ mice. In contrast, the malignant
intestinal tumours (b. and c.). The bars in c. represents the quantification of the bands obtained with an anti-active b-catenin Ab (anti-ABC; clone 8E7,
#05–665, Millipore) by scanning and analyzing the western blot with the Odyssey scanner and after normalization with b-actin.
doi:10.1371/journal.pone.0073872.g002
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Figure 3. Expression profiling analysis of tumor cell subpopulations from Apc1638N/+ and Apc1638N/+/KRASV12G intestinal tumours. (a.)
Hierarchical clustering and (b.) Principal Components Analysis (PCA) (both implemented in Partek) of Lin2CD24hiCD29+ (P3), Lin2CD24medCD29+/
Lin2CD24loCD29+ (P1+P2, merged gate) and Lin2 (bulk) tumor cells from 5 individual mice of each genotype (Apc1638N/+ and Apc1638N/+/KRASV12G).
For better visualization individual colours were used for each group and in b. ellipsoids were drawn around the three tumour populations.
doi:10.1371/journal.pone.0073872.g003
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transformation and accelerated adenoma-carcinoma sequence
brought about by the gut-specific expression of oncogenic KRAS
result in the establishment of a subpopulation of tumour-initiating
cells (estimated as 1 in approx. 76104 bulk tumour cells). The
observed lack of grafting potential by cells derived from Apc1638N/+
tumours is not surprising in view of previous studies showing that
both established adenoma cell lines and primary human adenomas
cannot form tumours even when injected at very high multiplic-
ities (,107) [27,28,29,30]. This is also in agreement with the
recent study by C. Blanpain and colleagues showing that benign
papillomas of the skin form secondary tumours at very low
frequencies exclusively when transplanted together with stroma
cells [31]. Of note, although the tumours here utilized for the
transplantation and expression profiling analyses were not
analysed by histopathology to maximize the number of cells
available for these assays, it is safe to assume that the employed
Apc1638N/+ tumours were adenomas, whereas those from Apc1638N/
+/KRASV12G animals were adenocarcinomas. This assumption is
based on our own 10-yrs long experience with the histo-
pathological analysis of the intestinal tumours found in these
inbred models, in agreement with the original descriptions
[10,11,12,14].
Overall, these results call for a revision of the current
operational definition of CSCs, especially when dealing with
benign lesions where the alleged subpopulation of stem-like
tumour cells are unlikely to form tumours upon transplantation
in immune-deficient animals. Alternatively, it is also plausible to
think that benign tumours do not encompass a bona fide
subpopulation of CSCs and that the true cancer stem cell
properties are acquired only upon malignant transformation.
CSCs enrichment (approx. 20–25 fold) was observed in the
CD24hiCD29+ subpopulation (here also referred to as P3) of
tumour cells from Apc1638N/+/KRASV12G mice. Notably, P3 cells
are characterized by increased intracellular b-catenin accumula-
tion thus indicating enhanced Wnt signalling activity and
validating previously proposed models [6,7]. These results are in
apparent contradiction with a recent publication showing that
oncogenic Kras activation does not result in the expansion of the
intestinal stem cell pool [25]. However, these observations were
made in an otherwise wild type genetic background (e.g. Apc-
proficient) rather than in the context of constitutive Wnt activation
resulting from loss of Apc gene function. As previously shown, Apc
and KRAS mutations appear to be synergistic in enhancing Wnt
signalling levels [14] and as such result in the expansion of the
CSC compartment (earmarked by b-catenin intracellular accu-
mulation) as shown here.
The CSCs concept [3] postulates that tumour masses are
organized in a hierarchical fashion with a subpopulation of stem-
like tumour cells endowed with self-renewal and differentiation
capacity which underlie tumour maintenance and growth.
Subpopulations of cancer cells enriched in CSCs have been
isolated from the majority of tumour types, including colon cancer
[15,16,17,18]. However, apart from their capacity to recapitulate
tumorigenesis when transplanted at limiting dilutions in immune-
deficient mice, CSCs need to be further characterized by
additional assays to test their self-renewal and differentiation
capacity. As shown here, the CSCs enriched in the P3
subpopulation of Apc1638N/+/KRASV12G intestinal tumours are
also characterized by self-renewal and differentiation: the relative
size of the CSC subpopulation remains constant in serially
transplanted tumours and the resulting malignant growths
encompass several differentiated cell types (enterocytes, Goblet
and Paneth cells) similar to the primary lesions. Notably, an
apparent increase in the relative presence of intestinal differenti-
ation lineages, namely Goblet, Paneth, and entero-endocrine cells,
was noted among the serially transplanted intestinal tumours when
compared with the primary Apc1638N/+/KRASV12G lesions. How-
ever, this was not reflected by a corresponding increase in the size
of the CD29/CD24 tumor subpopulations as observed by FACS
(Figure S3). Also, as these transplantation assays were subcutane-
ous and not orthotopic, it is likely that fluctuations in the incidence
of specific lineages results from the influence of the host
microenvironment on the CSCs’ self-renewal and differentiation
rates.
Expression profiling analysis of CD24hiCD29+ cells from
Apc1638N/+ and Apc1638N/+/KRASV12G tumours in comparison
with bulk and more differentiated tumour cells revealed several
biological processes likely to play functional roles in cancer
stemness. Gene ontology (GO) analysis [20] of the P3 signature
revealed a broad spectrum of biological and molecular functions
(Table S6). Of note, protein (mainly growth factors) binding
activity and extracellular matrix (ECM) structural constituents
seems to characterize the expression profile of the P3 subpopu-
lation of tumour cells. Whereas the former (growth factor binding)
may represent the main mechanism underlying the activity of
specific signalling pathways in CSCs, ECM components are likely
to play a rate/limiting supportive role in the regulation of essential
stem cell properties cells (eg, self-renewal, multipotency, prolifer-
ation, and differentiation). Stem cell niches are known to be
regulated by direct and paracrine interactions with supporting cells
and the extracellular matrix. Likewise, cancer-associated fibro-
blasts and other (e.g. inflammatory) cellular components of the
tumour microenvironment modulate the CSC niche not only by
releasing specific growth factors and cytokines but also through the
synthesis of modified ECM components rarely found in normal
tissues [32]. Nevertheless, one should not forget that the P3
subpopulation is enriched in stem-like tumour cells and by no
means represents purified CSCs. Hence, bioinformatic analysis of
the corresponding gene profiles might be confounded by the
presence of different cellular components which do not make
integral part of the CSC subpopulation and should be interpreted
with caution. Recently, a signature that predicts disease relapse in
colon cancer in man was developed based on mouse intestinal
stem cells (ISC) expressing high levels of the Lgr5 and EphB2 genes
[18]. Notably, comparison between the P3 and EphB2hi and Lgr5hi
signatures revealed no major overlap (7 and 13 genes respectively,
among which Lgr5 but not EphB2).
Of note, several Paneth cell specific genes including defensins
(Defa5, Defa 21/22, Defa24), secretory phospholipase A2 (Pla2g2a),
Fzd5 and matrix metallopeptidase 7 (Mmp7) are differentially
expressed in the P3 population [33]. On one hand this is expected
as the P3 (Lin2CD24hiCD29+) FACS gate is likely to overlap with
the CD24hiSSChi sorting gate previously employed to enrich for
Paneth cells from normal small intestinal epithelial cells [34,35].
Nevertheless, this observation is of potential interest in view of the
recently elucidated dual role of Paneth cells both as niche cells
(supporting Lgr5+ stem cells) [34,35], and as quiescent stem cells
[35,36]. Given the concomitant Lgr5 upregulation in P3 cells, it is
plausible that tumour-specific Paneth cells constitute the niche for
Lgr5+ CSCs in Apc1638N/+/KRASV12G adenocarcinomas [37].
Alternatively, quiescent (Paneth cell precursor) tumour stem cells
may provide a source of actively cycling Lgr5+ CSCs whose
function is then further supported by more mature Paneth cells.
Notably, the Apc- and Apc/KRAS-mutant genotypes could not be
resolved by HCA and PCA which does not allow us to pinpoint
qualitative differences between benign (Apc1638N/+) and more
malignant (Apc1638N/+/KRASV12G) CSCs. This is possibly due to
the relatively limited number of Apc1638N/+ vs. Apc1638N/+/
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KRASV12G tumour samples (n = 5 for each group) employed for the
comparative expression profiling analysis, insufficient to highlight
the allegedly more subtle differences between the two CSCs
genotypes. However, both in the HCA and PCA a trend is
apparent where the P1+2 and P3 tumour cell subpopulations
derived from Apc1638N/+ and Apc1638N/+/KRASV12G tumours
appear to cluster away from each other. In the future, the use of
more tumour samples and possibly the profiling of microdissected
tumour cells earmarked by nuclear b-catenin accumulation from
the two genotypes will shed more light on the more qualitative
differences between benign vs. malignant neoplastic stem cells.
Overall, our results show that cancer stemness in Apc-driven
intestinal tumorigenesis is underlined by an increased Wnt/b-
catenin signalling activity that is apparently decreased in more
differentiated tumour cells. As previously [7] and here reported
(Figure 2), in both human (colon) and mouse (upper GI tract) APC-
driven intestinal cancers cells with intracellular b-catenin accu-
mulation are clustered around the invasive front, thus suggesting
that factors secreted from the stromal microenvironment are likely
to play a role in the enhancement of Wnt signalling activity and
the maintenance of stem-like cancer cells. Also, the differential
upregulation in the P3 subpopulation of markers of both cycling
stem cells (Lgr5) and Paneth cells (defensins, matrix metallopro-
teases, and phospholipases) suggest that a niche similar to what
described for the normal intestinal crypt of the mouse is present
within adenocarcinomas. Further purification and (epi)genetic
profiling of the individual components of the CSC niche are
necessary to elucidate the cellular and molecular mechanisms
underlying cancer stemness in the digestive tract.
Materials and Methods
Ethics Statement
This study has been approved by the stichting Dier Experi-
menten Commissie (DEC), approval number EUR1383 and 2351.
During all mouse experimental interventions, animals have
been anesthetized to minimize pain and stress and maintained at
body temperature. Pain treatment for surgery has been done using
Temgesic. According to the criteria as described by the ‘‘Code of
Practice Dierproeven in het Kankeronderzoek’’, regular controls by animal
care personnel and our own scientist have been conducted
throughout the study to minimize suffering and discomfort due to
the intestinal and subcutaneous malignancies with coinciding
anaemia and weight loss.
Tumor Harvest and Dissociation
Tumors were harvested from Apc1638N/+ and Apc1638N/+/
KRASV12G mice aged 6 to 8 months. Tumors from individual
animals were pooled, minced with a razor blade, and suspended
into 10 ml digestion medium (RPMI, EGF 5 ng ml21, Hydrocor-
tisone 50 ng ml21, Insulin/Transferrin) supplemented with 10%
foetal calf serum and containing 4 mg ml21 collagenase A
(#11088793001, Roche), 0.1 mg ml21 Dispase II (#165859,
Roche) and 50 mg ml21 DNaseI (#DN-25, Sigma). Digestions
were conducted for 2 h at 37uC, 5% CO2. The final cell
suspension was filtrated through a 70- mm cell strainer (BD) and
stained with antibodies.
Cell Labelling, Flow Cytometry and Sorting
Immunostaining was performed in PBS supplemented with 2%
bovine calf serum at 4uC. Antibodies employed for labelling of
extracellular epitopes were: Biotin-conjugated rat anti-mouse
CD31 (#553371, PECAM-1 Monoclonal, BD, 1:100), Biotin-
conjugated rat anti-mouse CD45-Biotin (#553077, BD, 1:200),
Biotin-conjugated rat anti-mouse TER119-Biotin (#553672,BD,
1/100), Streptavidin-PerCP-Cy5.5 conjugate (#551419, BD,
1:1000), APC conjugated anti-mouse CD24 (#101813, Biolegend,
1:250), Phycoerythrin (PE) conjugated Hamster monoclonal to
CD29/integrin beta 1 (#ab36219, Abcam, 1:25), FITC conju-
gated rat monoclonal anti CD44 antibodies (#553133, BD,
1:200), mouse monoclonal anti L1CAM antibodies (#ab24345,
Abcam, 1:300)+secondary anti mouse-FITC antibodies, FITC
conjugated mouse monoclonal anti CD97 antibodies (#ab23490,
Abcam, 1:10). Antibody incubations were performed for 30 min.
at 4uC. For live/dead discrimination, cells were resuspended in
1 mg/ml Hoechst 33258 (#H3569, Invitrogen). Cell analysis and
sorting were performed with a FACSAriaTM (BD Biosciences),
equipped with a 100 mm nozzle. Hoechst fluorescence was
detected using 405 excitation and a BP450/40 emission filter,
FITC fluorescence was detected using 488 nm excitation and
LP502+ BP 530/30 emission filters, PE fluorescence was detected
using 488 nm excitation and LP556+ BP 575/26 emission filters,
PerCP-Cy5.5 fluorescence was detected using 488 nm excitation
and LP655+ BP 695/40 emission filters, APC fluorescence was
detected using 633 nm excitation and a BP660/20 emission filter.
Expression Profiling Analysis
Intestinal tumors from 3 Apc1638N/+ mice and 5 Apc1638N/+/
KRASV12G animals were employed for expression profiling by
oligonucleotide arrays. For each mouse, tumors were pooled and
digested as described above to allow sorting by FACS. From each
of the Lin2, Lin2CD24hiCD29+ and Lin2CD24medCD29+/
CD24loCD29+ (joined gate) populations, total RNA was isolated
from 104 sorted cells by RNAeasy Micro kit (QIAGEN) and
quality controlled by RNA 6000 Pico and Nano LabChip kits
(Agilent Technologies). Sample labelling, hybridization, staining
and scanning were performed on the Affymetrix MOE430 plus2.0
microarray platform using the Two-cycle Labelling kit according
to manufacturer’s instruction.
The raw profiling data are available under GEO number
GSE47772 and can be viewed at: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc =GSE47772.
For additional Materials and Methods see Methods S1.
Supporting Information
Figure S1 qPCR-based validation of genes differentially
expressed in the P3 population. Intestinal tumors from 2
individual Apc1638N/+ and 3 individual Apc1638N/+/KRASV12G
animals were digested to single cell suspensions and FACSorted
for isolation of 10,000 cells from each of the Lin- (blue bars), P3
(green bars) and P1+P2 (red bars; joined gate) populations. Total
RNA was isolated, converted into cDNA, and employed for 35
TaqmanH assays corresponding to the genes listed in Supplemen-
tary Table 2. All values were normalized to the expression of the
glyceraldehyde 3-phosphate dehydrogenase (Gapdh) house-keeping
gene. Similar results were obtained with the b-actin gene (Actb) as
reference.
(PDF)
Figure S2 Representative H&E images from a tumor
obtained by injecting Lin2 (bulk) cells from Apc1638N/+/
KRASV12G intestinal tumours.
(PDF)
Figure S3 Relative size of the CD24/CD29 FACS
subpopulations as observed in primary and serially
transplanted tumors from Apc1638N/+/KRASV12G mice.
‘‘Total tumors’’ refers to a total of 30 tumors analyzed by FACS in
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our laboratory between Augustus 2008 and December 2009,
employed for purposes other than serial transplantations. ‘‘Paren-
tal tumors’’ represent the primary Apc1638N/+/KRASV12G lesions
employed as source for the serial transplantations, here referred to
as 1st and 2nd round tumors. Despite some nearly-significant
fluctuations, the data indicate only minimal overall changes
between primary tumors and serially transplanted ones.
(PDF)
Figure S4 a. Western blot representative of the b-catenin
analysis of the FACSorted populations from Apc1638N/+/KRASV12G
intestinal tumours. Both the antibodies directed total (green, upper
panel) and actively signaling (de-phosphorylated; red, middle
panel) b-catenin are shown. b-actin (lower panel, red) was
employed as a loading control. Legend: M=molecular weight
marker; 1. Lin2 (bulk); 2. Lin2CD242CD292; 3. Lin2CD24+; 4.
Lin2CD29+; 5. Lin2P1+P2+P3; 6. Lin2P1; 7. Lin2P2; 8. Lin2P3.
b. Western blot analysis of total b-catenin in primary Apc1638N/+
intestinal tumours. The bars represents the quantification of the
bands by scanning and analysing the western blot with the
Odyssey scanner and after normalization with b-actin. When the
anti-active b-catenin Ab was employed, hardly any signal could be
detected in bulk and sorted Apc1638N/+ intestinal tumour cells.
(TIF)
Table S1 Subcutaneous transplantation of tumour cells from
Apc1638N/+/KRASV12G mice in immune-incompetent mice sorted
with common CSC surface antigen markers.
(PDF)
Table S2 List of the 35 genes and corresponding TaqmanH
assays employed to validate the microarray data by qRT-PCR (see
Supplementary Figure 2).
(PDF)
Table S3 P3 signature based on P3 vs. Lin2 comparison.
ANOVA (3 ways) analysis led to an initial list of 746 differential
expressed probsets (n = 602 non-redundant, annotated RefSeq
Genes) with a FDR of 0.05 and $2 fold difference. RefSeq
Transcript IDs, Probeset IDs and the lowest corresponding P-
value (P3 vs Lin2) are listed. Uploading/mapping this list in
Biobase-Explain resulted in 574 annotated genes.
(XLS)
Table S4 P3 signature based on P3 vs. P1+P2 comparison
(n= 808 annotated genes). ANOVA (3 ways) analysis led to an
initial list of 1062 differential expressed probsets [851 non-
redundant, annotated RefSeq genes) with a FDR of 0.05 and $2
fold difference. RefSeq Transcript IDs, Probeset IDs and the
lowest corresponding p-value (P3 vs. P1+P2) are listed. Upload-
ing/mapping this list in Biobase-Explain resulted in 808 annotated
genes.
(XLS)
Table S5 P3 signature (intersection between P3 vs. Lin- and P3
vs. P1+P2 (n= 462 annotated genes). ANOVA (3 ways) analysis
led to an initial list of 1062 differential expressed probesets (851
non-redundant, annotated RefSeq genes) with a FDR of 0.05 and
$2-fold difference. Gene Symbol, Gene Title, RefSeq Transcript
IDs, Probeset IDs and the lowest corresponding P-values (P3 vs.
Lin- and P3 vs. P1+P2) are listed. Uploading/mapping this list in
Biobase-Explain resulted in 462 annotated genes.
(XLS)
Table S6 Gene Ontology (GO) Analysis of the P3/intersection
signature (see Supp. Table 5). Within Biobase/Explain, the
Functional Analysis module enables to explore statistically
overrepresented and underrepresented groups in a data set
according to Gene Ontology classification (19). Matched terms
of the selected Function category are given in each row of the
output table. The table presents (from left to right) the GO
identifier, Gene symbols, the GO term description, the number of
hits from the input set to the ontology group, the size of the group
in the database, expected hits, and the P-value of the observation.
(XLS)
Methods S1 See Supplementary Materials and Methods
file.
(DOC)
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